Is Lisuridum [INN-Latin] Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Lisuridum [INN-Latin]? Is Lisuridum [INN-Latin] safe for nursing mother and child? Does Lisuridum [INN-Latin] extracts into breast milk? Does Lisuridum [INN-Latin] has any long term or short term side effects on infants? Can Lisuridum [INN-Latin] influence milk supply or can Lisuridum [INN-Latin] decrease milk supply in lactating mothers?
Lisuridum [INN-Latin] lactation summary
![Lisuridum [INN-Latin] is dangerous in breastfeeding](/images/breastfeeding/dangerous-in-breastfeeding.jpg "Lisuridum [INN-Latin] breastfeeding")
- DrLact safety Score for Lisuridum [INN-Latin] is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Lisuridum [INN-Latin] may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Lisuridum [INN-Latin] may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Lisuridum [INN-Latin] .
- Usage of Lisuridum [INN-Latin] is in contradiction to breastfeeding hence if it is must to use Lisuridum [INN-Latin] and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Lisuridum [INN-Latin] usage in lactation
Anti-Parkinson drug, dopamine-agonist and synthetic ergotamine derivative that may inhibit prolactin release.
Answer by DrLact: About Lisuridum [INN-Latin] usage in lactation
Lisuridum [INN-Latin] is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. It lowers serum prolactin and is approved in some countries for lactation suppression. Some experts recommend Lisuridum [INN-Latin] as a safer alternative to bromocriptine for lactation suppression, but others recommend avoiding all lactation suppressants.[1][2] Data are insufficient recommend one treatment for lactation suppression over another.[3]
Lisuridum [INN-Latin] Possible Effects in Breastfeeding
Lisuridum [INN-Latin] suppresses serum prolactin increases in a dose-related fashion.[4][5] Comparative studies have found Lisuridum [INN-Latin] comparable in efficacy to bromocriptine, although rebound lactation occurred in more patients treated with Lisuridum [INN-Latin] 0.4 mg daily than in those treated with bromocriptine 5 mg daily.[6][7] Rebound lactation appears to be less with a higher dose of 0.6 mg daily and with 15 days of therapy rather than 10 days.[8][9]
Alternate Drugs
Pramipexole(Unsafe)
Ropinirole(Unsafe)
Levodopa(Unsafe)
Cabergoline(Unsafe)
Bromocriptine(Unsafe)
Amantadine(Low Risk)
Lisuride(Dangerous)
Pramipexole(Unsafe)
Ropinirole(Unsafe)
Cabergoline(Unsafe)
Bromocriptine(Unsafe)
Lisuride(Dangerous)
Lisuride(Dangerous)